Immunome (NASDAQ:IMNM) Director Sells 16,906 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 16,906 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $24.20, for a total transaction of $409,125.20. Following the transaction, the director owned 108,504 shares in the company, valued at $2,625,796.80. The trade was a 13.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Stock Up 2.1%

Shares of Immunome stock traded up $0.49 on Tuesday, hitting $24.39. 1,561,508 shares of the company were exchanged, compared to its average volume of 1,722,826. The company has a 50-day moving average price of $20.99 and a 200 day moving average price of $21.83. The stock has a market capitalization of $2.76 billion, a price-to-earnings ratio of -10.25 and a beta of 2.07. Immunome, Inc. has a 1-year low of $7.96 and a 1-year high of $27.65.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.12. Research analysts forecast that Immunome, Inc. will post -2.06 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on IMNM shares. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Leerink Partners reduced their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research report on Friday, May 15th. Barclays began coverage on Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Immunome in a research note on Wednesday, May 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.17.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Immunome by 44.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock worth $316,000 after purchasing an additional 14,398 shares during the last quarter. Creative Planning purchased a new stake in Immunome during the second quarter worth approximately $167,000. Rhumbline Advisers boosted its position in Immunome by 22.0% during the 2nd quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock worth $1,008,000 after purchasing an additional 19,526 shares during the period. The Manufacturers Life Insurance Company raised its position in Immunome by 3.6% in the second quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock valued at $2,612,000 after purchasing an additional 9,686 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Immunome during the second quarter worth about $1,021,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.